Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/625
Type: Artigo de periódico
Title: Current Patient Management of Chronic Myeloid Leukemia in Latin America A Study by the Latin American Leukemia Net (LALNET)
Author: CORTES, Jorge
SOUZA, Carmino De
AYALA-SANCHEZ, Manuel
BENDIT, Israel
BEST-AGUILERA, Carlos
ENRICO, Alicia
HAMERSCHLAK, Nelson
PAGNANO, Katia
PASQUINI, Ricardo
MEILLON, Luis
Abstract: BACKGROUND: Treatment recommendations have been developed for management of patients with chronic myeloid leukemia (CML). METHODS: A 30-item multiple-choice questionnaire was administered to 435 hematologists and oncohematologists in 16 Latin American countries. Physicians self-reported their diagnostic, therapeutic, and disease management strategies. RESULTS: Imatinib is available as initial therapy to 92% of physicians, and 42% of physicians have access to both second-generation tyrosine kinase inhibitors. Standard-dose imatinib is the preferred initial therapy for most patients, but 20% would manage a young patient initially with an allogeneic stem cell transplant from a sibling donor, and 10% would only offer hydroxyurea to an elderly patient. Seventy-two percent of responders perform routine cytogenetic analysis for monitoring patients on therapy, and 59% routinely use quantitative polymerase chain reaction. For patients who fail imatinib therapy, 61% would increase the dose of imatinib before considering change to a second-generation tyrosine kinase inhibitor, except for patients aged 60 years, for whom a switch to a second-generation tyrosine kinase inhibitor was the preferred choice. CONCLUSIONS: The answers to this survey provide insight into the management of patients with CML in Latin America. Some deviations from current recommendations were identified. Understanding the treatment patterns of patients with CML in broad population studies is important to identify needs and improve patient care. Cancer 2010;116:4991-5000. (C) 2070 American Cancer Society.
Subject: chronic myeloid leukemia
imatinib
dasatinib
nilotinib
tyrosine kinase inhibitors
guidelines
Latin America
survey
Country: Estados Unidos
Editor: JOHN WILEY & SONS INC
Rights: fechado
Identifier DOI: 10.1002/cncr.25273
Address: http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000283397700015&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord
http://dx.doi.org/10.1002/cncr.25273
Date Issue: 2010
Appears in Collections:HEMO - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
art_CORTES_Current_Patient_Management_of_Chronic_Myeloid_Leukemia_2010.pdfpublished version732.83 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.